The program was funded with a cooperative agreements between the NIDDK and the TaMADOR consortium institutions few years ago but it will now continue putting emphasis on the development of assays of importance in type 1 diabetes clinical research (see https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-031.html). The Principal Investigators Dr Andrew Hoofnagle (University of Washington, Seattle), Dr. Michael MacCoss (University of Washington, Seattle), Dr. Jun Qu (University at Buffalo), and Dr. Weijun Qian (PNNL) will continue leading this effort on type 1 diabetes. Within the RFA we indicated a list of potential targets (e.g. glucagon and other pro-glucagon derived peptides, C-peptide, insulin, pro-insulin, Glycated CD59, Islet Amyloid Polypeptide (IAPP), Chromogranin A (CgA), and chromogranin B (CgB)) that the group could be working on but we are looking forward to the advisory group and community feedback for determining the consortium priorities.

The Hoofnagle lab has developed an LC-MS/MS assay to measure insulin and C-peptide.
https://www.sciencedirect.com/science/article/pii/S2667145X22000189?via%3Dihub

The measurement of insulin and C-peptide provides a valuable tool for the clinical evaluation of hypoglycemia. In research, these biomarkers are used together to better understand hyperinsulinemia, hepatic insulin clearance, and beta cell function. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is an attractive approach for the analysis of insulin and C-peptide because the platform is specific, can avoid certain limitations of immunoassays, and can be multiplexed. Previously described LC-MS/MS methods for the simultaneous quantification of insulin and C-peptide measure the intact analytes and most have relied on immunoaffinity enrichment. These approaches can be limited in terms of sensitivity and interference from auto-antibodies, respectively. We have developed a novel method that does not require antibodies and uses proteolytic digestion to yield readily ionizable proteotypic peptides that enables the sensitive, specific, and simultaneous quantitation of insulin and C-peptide.

Multiplex quantification of protein/peptide hormones and biomarkers involved in obesity and diabetes will facilitate translational scientific research. The NIDDK recently funded several projects that aim to use targeted MS approaches for quantifying human plasma/serum proteins and peptides of main interest to the obesity and diabetes research community. This meeting will focus on advances by TArgeted Mass spectrometry Assays for Diabetes and Obesity Research (TAMADOR) consortium.

Register now: https://panoramaweb.org/TAMADOR/wiki-page.view?name=Bethesda-TaMADOR-Meeting

The NIDDK recently started a program for developing mass spectrometric assays for proteins and peptides of primary interest to the obesity and diabetes research community. These assays should be highly reproducible, easily transferable to other laboratories, and validated in human plasma or serum. Examples, of proteins and peptides that are of potential interest include insulin, glucagon, c-pepitide, glycated CD59, Adiponectin, Leptin, Resistin, Neuropeptide Y, Alpha-melanocyte-stimulating hormone, Peptide YY, Glucagon-like peptide 1, Ghrelin, Adrenocorticotropin, Corticotropin-releasing hormone, Gastrin, Cholecystokinin, Secretin, Vasoactive intestinal peptide, gastric-inhibitory peptide, gastrin-releasing peptide, motilin, pancreatic polypeptide, RBP4, myostatin, FGF21).

We will introduce the TaMADOR (Targeted Mass Spectrometric Assays for Diabetes and Obesity Research) program and discuss how we might proceed in developing, validating, and implementing MS assays of interest to the Obesity and Diabetes community.

Workshop on Thu Jun 03, 2021 from 10am to noon Pacific Time.

Register here at: https://msacl-org.zoom.us/meeting/register/tZArf-uhqz0jEtdLLDHrG8qUP7kMrUcwFyez

Two NIDDK programs, one focused on Type 1 Diabetes (https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-17-019.html) and one focused on Obesity (https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-19-001.html) are working together to develop and share quantitative protein assays. Andy Hoofnagle's lab at the University of Washington is working on Type 1 Diabetes. Jenny Van Eyk's and Wei-Jun Qian's labs at Cedars-Sinai and PNNL respectively are working on Obesity. To leverage each other's capabilities and strengths we have formed a working group that we call TaMADOR (Targeted Mass Spectrometry Assays for Diabetes and Obesity Research).